These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37039036)

  • 21. Novel
    Malik S; Hassan S; Eşkazan AE
    Expert Rev Hematol; 2021 Nov; 14(11):975-978. PubMed ID: 34608829
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population.
    Kockerols CCB; Janssen JJWM; Blijlevens NMA; Klein SK; Van Hussen-Daenen LGM; Van Gorkom GGY; Smit WM; Van Balen P; Biemond BJ; Cruijsen MJ; Corsten MF; Te Boekhorst PAW; Koene HR; Van Sluis GL; Cornelissen JJ; Westerweel PE
    Haematologica; 2023 Jan; 108(1):240-244. PubMed ID: 36073515
    [No Abstract]   [Full Text] [Related]  

  • 23. Asciminib in chronic myeloid leukemia.
    Assanto GM; Scalzulli E; Breccia M
    Drugs Today (Barc); 2022 Oct; 58(10):479-489. PubMed ID: 36305542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A kinase inhibitor which specifically targets the ABL myristate pocket (STAMP), but unlike asciminib crosses the blood-brain barrier.
    Manley PW; Huth F; Moussaoui S; Schoepfer J
    Bioorg Med Chem Lett; 2022 Mar; 59():128577. PubMed ID: 35065232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study.
    Yuda J; Doki N; Matsuoka H; Yokota T; Tomita A; Takahashi N; Matsumura I; Kubo K; Goto T; Kirito K; Maki A; Aoki M; Allepuz A; Minami Y
    Cancer Med; 2023 Feb; 12(3):2990-2998. PubMed ID: 36168187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment-free remission after third-line therapy with asciminib in chronic myeloid leukemia with an atypical e19a2 BCR::ABL1 transcript and T315I mutation.
    Ernst P; Rinke J; Franke GN; Dicker F; Haferlach T; Ernst T; Hochhaus A
    Leukemia; 2024 Sep; 38(9):2037-2040. PubMed ID: 38965368
    [No Abstract]   [Full Text] [Related]  

  • 27. Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
    Schoepfer J; Jahnke W; Berellini G; Buonamici S; Cotesta S; Cowan-Jacob SW; Dodd S; Drueckes P; Fabbro D; Gabriel T; Groell JM; Grotzfeld RM; Hassan AQ; Henry C; Iyer V; Jones D; Lombardo F; Loo A; Manley PW; Pellé X; Rummel G; Salem B; Warmuth M; Wylie AA; Zoller T; Marzinzik AL; Furet P
    J Med Chem; 2018 Sep; 61(18):8120-8135. PubMed ID: 30137981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Asciminib for chronic myeloid leukaemia: Next questions.
    Shanmuganathan N; Hughes TP
    Br J Haematol; 2022 Nov; 199(3):322-331. PubMed ID: 35729850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
    Halbach S; Hu Z; Gretzmeier C; Ellermann J; Wöhrle FU; Dengjel J; Brummer T
    Cell Commun Signal; 2016 Feb; 14():6. PubMed ID: 26912052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Asciminib in chronic myeloid leukemia: a STAMP for expedited delivery?
    Padala S; Cortes J
    Haematologica; 2023 Nov; 108(11):2913-2918. PubMed ID: 37102603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells.
    Chatain N; Baumeister J; Szymanski de Toledo MA; Wong DWL; Gupta S; Pannen K; Junge B; Brümmendorf TH; Boor P; Koschmieder S
    Leukemia; 2024 Aug; 38(8):1825-1830. PubMed ID: 38906962
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allosteric enhancement of the BCR-Abl1 kinase inhibition activity of nilotinib by cobinding of asciminib.
    Oruganti B; Lindahl E; Yang J; Amiri W; Rahimullah R; Friedman R
    J Biol Chem; 2022 Aug; 298(8):102238. PubMed ID: 35809644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Asciminib (Scemblix): A third-line treatment option for chronic myeloid leukemia in chronic phase with or without T315I mutation.
    Monestime S; Al Sagheer T; Tadros M
    Am J Health Syst Pharm; 2023 Jan; 80(2):36-43. PubMed ID: 36197958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia.
    Roskoski R
    Pharmacol Res; 2022 Apr; 178():106156. PubMed ID: 35257901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases.
    Li YF; Combes FP; Hoch M; Lorenzo S; Sy SKB; Ho YY
    Clin Pharmacokinet; 2022 Oct; 61(10):1393-1403. PubMed ID: 35764773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Asciminib for the treatment of patients with chronic myeloid leukemia.
    Cortes J
    Clin Adv Hematol Oncol; 2021 Apr; 19(4):207-208. PubMed ID: 33989269
    [No Abstract]   [Full Text] [Related]  

  • 37. Asciminib: First Approval.
    Deeks ED
    Drugs; 2022 Feb; 82(2):219-226. PubMed ID: 35041175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Synergistic Combination Against Chronic Myeloid Leukemia: An Intra-molecular Mechanism of Communication in BCR-ABL1 Resistance.
    El Rashedy AA; Appiah-Kubi P; Soliman MES
    Protein J; 2019 Apr; 38(2):142-150. PubMed ID: 30877503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Asciminib: an investigational agent for the treatment of chronic myeloid leukemia.
    Breccia M; Colafigli G; Scalzulli E; Martelli M
    Expert Opin Investig Drugs; 2021 Aug; 30(8):803-811. PubMed ID: 34130563
    [No Abstract]   [Full Text] [Related]  

  • 40. The outcome of post-transplant asciminib in patients with chronic myeloid leukaemia.
    Fernando F; Innes AJ; Claudiani S; Pryce A; Hayden C; Byrne J; Gallipoli P; Copland M; Apperley JF; Milojkovic D
    Bone Marrow Transplant; 2023 Jul; 58(7):826-828. PubMed ID: 37015970
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.